ValiRx (VAL) Stock Rating Reaffirmed by Beaufort Securities

ValiRx (LON:VAL)‘s stock had its “speculative buy” rating reiterated by investment analysts at Beaufort Securities in a research report issued to clients and investors on Tuesday, December 19th.

Shares of ValiRx (LON:VAL) traded up GBX 0.05 ($0.00) on Tuesday, hitting GBX 4.88 ($0.07). The stock had a trading volume of 3,967,342 shares, compared to its average volume of 28,510,000. The firm has a market cap of $12.12 and a P/E ratio of -81.25. ValiRx has a 12 month low of GBX 0.90 ($0.01) and a 12 month high of GBX 7.75 ($0.11).

TRADEMARK VIOLATION WARNING: “ValiRx (VAL) Stock Rating Reaffirmed by Beaufort Securities” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2018/01/12/valirx-val-rating-reiterated-by-beaufort-securities.html.

About ValiRx

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply